Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01465139 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate CDX-301 (rhuFlt3L) in Healthy Volunteers
A Phase 1 study, sponsored by Celldex Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT01465139 is a Phase 1 study that has completed, run by Celldex Therapeutics. The registered enrollment target is 30 participants.
The verdict
NCT01465139, a Phase 1 study, has completed, sponsored by Celldex Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
CDX-301 is a protein that stimulates the growth of bone marrow stem cells and certain immune cells. This study is testing CDX-301 in healthy volunteers who will be monitored for safety and biological response for approximately one month or more.
Interventions
- DRUG CDX-301
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2011-10 |
| Est. Completion | 2013-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01465139
The ClinicalTrials.gov registry entry for NCT01465139 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celldex Therapeutics, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CDX-301 is the first listed.
NCT01465139 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01465139 about?
NCT01465139 is a clinical study titled "A Study to Evaluate CDX-301 (rhuFlt3L) in Healthy Volunteers". CDX-301 is a protein that stimulates the growth of bone marrow stem cells and certain immune cells. This study is testing CDX-301 in healthy volunteers who will be monitored for safety and biological response for approximately one month or more.
What is the current status of trial NCT01465139?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2011-10. Estimated completion is 2013-01.
What interventions are being tested in trial NCT01465139?
The interventions under investigation include: CDX-301 (DRUG).
Who is sponsoring clinical trial NCT01465139?
This trial is sponsored by Celldex Therapeutics, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.